The U.S. Food and Drug Administration (FDA) on Wednesday approved Pfizer Inc.’s PFE TUKYSA (tucatinib) in combination with ...

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return potential. Click to read more on PFE.

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Spread the loveThe pharmaceutical industry’s pursuit of effective weight-loss solutions has been nothing short of a modern ...

ast June, when AI drug discovery startup Chai Discovery was just 15 months old, it released a new model that could design antibodies. Nearly 20 pharma companies reached out to talk. “It was like we ...

July 22 (Reuters) - Pfizer (PFE.N), opens new tab said on Wednesday the U.S. Food and Drug Administration had granted priority review to its application seeking expanded approval for its prostate ...

Pfizer PFE is facing one of the steepest patent cliffs in the large-cap pharma space. The company expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) cliff in the ...